Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?

Multiple Sclerosis Journal - Experimental, Translational and Clinical
S L MindenLisa I Iezzoni

Abstract

Disease-modifying therapies benefit individuals with relapsing forms of multiple sclerosis, but their utility remains unclear for those without relapses. To determine disease-modifying therapy use and costs in 2009, compare use in 2009 and 2000, and examine compliance with evidence-based guidelines. We determined the extent and characteristics of disease-modifying therapy use by participants in the Sonya Slifka Longitudinal Multiple Sclerosis Study (Slifka) in 2000 (n=2156) and 2009 (n=2361) and estimated out-of-pocket and total (payer) costs for 2009. Two multivariable logistic regressions predicted disease-modifying therapy use. Disease-modifying therapy use increased from 55.3% in 2000 to 61.5% in 2009. In 2009, disease-modifying therapy use was reported by 76.5% of participants with relapsing-remitting multiple sclerosis, 73.2% with progressive-relapsing multiple sclerosis, 62.5% with secondary progressive multiple sclerosis, and 41.8% with primary progressive multiple sclerosis. Use was significantly associated with relapsing-remitting multiple sclerosis, shorter duration of illness, one to two relapses per year, non-ambulatory symptoms, using a cane, younger age, higher family income, and having health insurance. Average ...Continue Reading

References

Aug 19, 1995·BMJ : British Medical Journal·D G Altman, J M Bland
Jan 24, 2002·Neurology·D S GoodinUNKNOWN Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Pra
Apr 9, 2002·Multiple Sclerosis : Clinical and Laboratory Research·M S FreedmanUNKNOWN Paris Workshop Group
Dec 31, 2002·Lancet·Hans-Peter HartungUNKNOWN Mitoxantrone in Multiple Sclerosis Study Group (MIMS)
Jun 27, 2003·The New England Journal of Medicine·Elizabeth A McGlynnEve A Kerr
Jun 29, 2004·Multiple Sclerosis : Clinical and Laboratory Research·Ludwig Kappos
Mar 1, 2005·Multiple Sclerosis : Clinical and Laboratory Research·Albert C LoTimothy L Vollmer
Feb 8, 2006·Multiple Sclerosis : Clinical and Laboratory Research·S L MindenD C Hoaglin
Jun 21, 2008·Multiple Sclerosis : Clinical and Laboratory Research·S MindenJ Outley
Dec 10, 2009·Multiple Sclerosis : Clinical and Laboratory Research·Roisín LonerganNiall Tubridy
Jul 20, 2010·Journal of Neurology, Neurosurgery, and Psychiatry·Marcus KochUNKNOWN UBC MS Clinic Neurologists
Nov 12, 2010·Journal of Managed Care Pharmacy : JMCP·Jeremy A SchaferPatrick P Gleason
Feb 23, 2013·Neurology·Annette M Langer-GouldGary S Gronseth
Mar 1, 2012·Neurology. Clinical Practice·Omar KhanChristopher J Barnes
Sep 11, 2013·Neurology·David H MattsonThomas S D Getchius
Mar 17, 2015·Lancet Neurology·Daniel OntanedaJeremy Chataway
Mar 20, 2015·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A SignoriM P Sormani
Mar 17, 2016·International Journal of Medical Informatics·Derk L ArtsHenk C P M van Weert
Oct 19, 2016·Current Medical Research and Opinion·Aseel Bin SawadFatema Turkistani
Feb 17, 2017·Patient Preference and Adherence·Gustavo SaposnikPhilippe N Tobler
Jun 9, 2017·Expert Review of Neurotherapeutics·Emanuele D'AmicoSalvatore Cottone
Jul 5, 2017·Multiple Sclerosis : Clinical and Laboratory Research·W Oliver Tobin, Brian G Weinshenker
Jul 5, 2017·Multiple Sclerosis : Clinical and Laboratory Research·John R Corboy
Sep 2, 2017·Chinese Journal of Integrative Medicine·Yang XuAn-Sheng Sun

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved